Processing...
Clinical Trials for Breast Cancer
Search
Search
There are 332 active trials for advanced/metastatic breast cancer.
Click on a trial to see more information.
332 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Open-label dose-escalation/expansion study of oral RGT-490 monotherapy, a selective mutant PI3Kα inhibitor, in adults with locally advanced unresectable or metastatic solid tumors harboring activating PIK3CA mutations after at least one prior therapy. Expansion focuses on HR+/HER2− advanced breast cancer; patients with prior PI3Kα inhibitor exposure or diabetes requiring antihyperglycemic medication are excluded.
ClinicalTrials.gov ID: NCT07524322
TrialFetch AI summary: Enrolling postmenopausal women or women on ovarian suppression with ER+/HER2− metastatic or locally advanced breast cancer, measurable disease, progression after prior metastatic endocrine therapy and prior CDK4/6 inhibitor, and ≤2 prior metastatic chemotherapy regimens. All patients receive oral single-agent HLD-0117, an investigational ER-targeting RIPTAC designed to bind ER and BRD4/essential survival protein to induce proximity-driven tumor-cell death.
ClinicalTrials.gov ID: NCT07524855
TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced selected solid tumors, including SCLC, extrapulmonary high-grade neuroendocrine/small-cell carcinomas, NSCLC, prostate, ovarian, renal, HNSCC, hepatic, gastric, and triple-negative breast cancers, after progression/relapse/intolerance to at least one standard systemic therapy. All patients receive dose-escalated oral EXS74539/REC-4539 monotherapy, a selective reversible LSD1/KDM1A epigenetic inhibitor, to define safety and MTD with preliminary efficacy assessment.
ClinicalTrials.gov ID: NCT07517198
TrialFetch AI summary: Adults with ECOG 0–1 and progressive locally advanced/unresectable or metastatic cervical/vulvar cancer, small-cell lung cancer, gastric/GEJ cancer, or pancreatic ductal adenocarcinoma after standard options receive IV AVA6103 monotherapy on q2w or q3w schedules. AVA6103 is a FAP-activated exatecan peptide-drug conjugate designed to release a topoisomerase I inhibitor payload in the tumor microenvironment.
ClinicalTrials.gov ID: NCT07454642
TrialFetch AI summary: Adults with previously treated, progressive SSTR-positive metastatic or recurrent breast cancer (ECOG 0–2) receive IV 177Lu-DOTATATE every 8 weeks for four doses. This peptide receptor radionuclide therapy binds somatostatin receptors, particularly SSTR2, to deliver beta radiation to receptor-expressing tumor cells.
ClinicalTrials.gov ID: NCT04529044
TrialFetch AI summary: Patients with ECOG 0–2 and measurable, unresectable locally advanced or metastatic solid tumors, including colorectal cancer, NSCLC, breast cancer, and upper GI adenocarcinomas; expansion focuses on refractory colorectal cancer and NSCLC. All receive IV IM-1617, an antibody–drug conjugate targeting an undisclosed receptor tyrosine kinase and delivering the HC74 topoisomerase-I inhibitor payload.
ClinicalTrials.gov ID: NCT07578571
TrialFetch AI summary: Adults with unresectable or metastatic HR-positive/HER2-negative breast cancer previously treated with endocrine therapy plus a CDK4/6 inhibitor receive oral IEV407 alone or with fulvestrant or letrozole. IEV407’s molecular target and mechanism have not been publicly disclosed.
ClinicalTrials.gov ID: NCT07604571
TrialFetch AI summary: Adults with ECOG 0–1 and previously treated metastatic castration-resistant prostate adenocarcinoma or metastatic invasive breast cancer receive nine infusions of autologous fresh peripheral blood mononuclear cells armed ex vivo with HER2Bi. This anti-CD3 × anti-HER2 bispecific antibody redirects CD3-positive T cells against HER2-expressing tumor cells without prolonged T-cell expansion.
ClinicalTrials.gov ID: NCT07441889
TrialFetch AI summary: Adults with previously treated, advanced solid tumors harboring oncogenic PIK3CA mutations, including endometrial, HR-positive/HER2-negative or HER2-low breast, head and neck, gynecologic, and colorectal cancers, receive oral CGT6297. CGT6297 is a mutant-selective, wild-type-sparing allosteric PI3Kα inhibitor with activity against PIK3CA H1047R and potentially E545K mutations.
ClinicalTrials.gov ID: NCT07383506
TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors that have progressed on, or are unsuitable or intolerant of, standard therapy receive once-daily oral SHY-ONC6. SHY-ONC6 is a small-molecule proteasome inhibitor targeting selected AAA+ ATPases in the 19S regulatory particle to disrupt ubiquitinated protein processing and promote apoptosis.
ClinicalTrials.gov ID: NCT07705334